Tato čerstvá zpráva by mohla akcii $NVO nastartovat: Novo Nordisk (NVO) said Wednesday that oral semaglutide 25 mg (Wegovy in a pill) delivered 16.6% weight loss in people with obesity in a phase 3 trial compared with 2.7% for placebo in 64-week trial. 34.4% achieved at least 20% weight loss, versus 2.9% for placebo.
The safety and tolerability profile of oral semaglutide was…